FDA clears AlloVir's ALVR106 application in respiratory viruses

 

• The FDA has cleared AlloVir's (NASDAQ:ALVR) Investigational New Drug (IND) application for ALVR106, an allogeneic, off-the-shelf virus-specific T cell therapy designed to target infections and diseases caused by respiratory syncytial virus (RSV), influenza, parainfluenza virus (PIV), and human metapneumovirus (hMPV).
• The IND enables AlloVir to initiate a Phase 1/2 proof-of-concept study in allogeneic and autologous hematopoietic stem cell transplant (HSCT) patients with respiratory infections caused by RSV, influenza, PIV or hMPV. The study is expected to begin in 2021.
• https://seekingalpha.com/news/3645249-fda-clears-allovirs-alvr106-application-in-respiratory-viruses